| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | DOJOLVI (triheptanoin) | Glut1 DS patients with the movement disorder phenotype | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | Aceneuramic acid extended release (Ace-ER) | GNE Myopathy | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | DTX301 - (Enh3ance) | Ornithine Transcarbamylase (OTC) Deficiency | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | DOJOLVI (triheptanoin) | Glut1 DS patients with the movement disorder phenotype | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | Aceneuramic acid extended release (Ace-ER) | GNE Myopathy | Phase 3 | Trial Discontinued | Oral | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | GTX-102 - (Aurora) | Other Angelman syndrome genotypes | Phase 3 | Trial Planned | Intrathecal | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | GTX-102 - (Aurora) | Angelman syndrome (AS) | Phase 2/3 | Ongoing | Intrathecal | Genetic Disorder |
| Ultragenyx Pharmaceutical Inc. | Setrusumab (BPS-804) - (ORBIT) | Osteogenesis Imperfecta | Phase 2/3 | Data Released | Intravenous | Orthopedic |